<DOC>
	<DOC>NCT01096472</DOC>
	<brief_summary>The aim of this study is to determine the efficacy and safety of a topical application of the combinational cream LAS41003 compared to application of its mono-substances after once daily treatment in patients with inflammatory tinea pedis.</brief_summary>
	<brief_title>Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<criteria>presence of tinea pedis caused by dermatophytes on one or both feet, characterized by physician's global assessment score of 2 ("notable signs and symptoms exist") or 3 ("prominent signs and symptoms exist") at baseline; the physical examination must be without other disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study; female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner; patients must be willing and able to comply with the requirements of the trial protocol; written informed consent obtained. patients with hyperkeratotic chronic plantar tinea pedis (moccasin type); receiving systemic therapy with cytotoxic or immunosuppressive drugs either concurrently or within 12 weeks before the baseline visit; oral antifungal therapies within three months before study entry (8 months for oral terbinafine), systemic antibiotic or corticosteroid treatment, topical corticosteroids within 30 days before study entry; patients with diabetes; patients with compromised circulation; evidence of drug or alcohol abuse; pregnancy or nursing; symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before the treatment phase and during the study; participation in the treatment phase of another clinical study within the last four weeks prior to the first administration of investigational drug in this study; known allergic reactions to components of the study preparations, hypersensitivity against cetylstearyl alcohol; treatment with systemic or locally acting medications which might counter or influence the study aim within two weeks before the treatment phase of the study (e.g. glucocorticosteroids);</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Tinea pedis</keyword>
</DOC>